北陆药业(300016.SZ)发布前三季度业绩，归母净利润4417.69万元，增长81.10%

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 873 million yuan, representing a year-on-year growth of 19.59% [1] - The net profit attributable to shareholders of the listed company was 44.1769 million yuan, showing a year-on-year increase of 81.10% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.6758 million yuan, reflecting a year-on-year growth of 33.53% [1] - Basic earnings per share were reported at 0.087 yuan [1]